The CSL Limited (ASX: CSL) share price hit a new all-time high of $142.04 yesterday afternoon.
Shares of the healthcare company are up 262% in the past 5 years, or 972% since debut back in the 1990s.
According to Google Finance, CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property.
The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohaematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties.
Shares have rocketed higher after the company announced a recent profit upgrade that reversed previous negative market sentiment.
At a share price of $142.04, CSL Limited shares trade on 37 times forward earnings estimates, and a forecast dividend yield of 1.21%.
